Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform and removed the firm’s price target on the shares after the company announced that VERITAC-2 had missed on the all-comers co-primary ...
SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the Oppenheimer Movers in Rare Disease Summit being ...
TipRanks on MSN
Vicore Pharma to participate in rare disease summit
Vicore Pharma Holding AB ( ($SE:VICO) ) just unveiled an announcement. Vicore Pharma Holding AB announced its participation in the Oppenheimer ...
Hosted on MSN
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results
On Tuesday, Oppenheimer increased its price target for Trevi Therapeutics Inc. (NASDAQ:TRVI) to $23 from $20, while maintaining an Outperform rating. This heightened optimism is driven by positive ...
Please contact your Oppenheimer representative to register for the Movers in Rare Disease Summit and to schedule a 1x1 meeting with Dr. Mor and Chemomab management.
Oppenheimer noted that the trial results address market skepticism that emerged following initial data released last September, prior to changes that aligned the trial design more closely with current ...
STOCKHOLM, SE / ACCESS Newswire / December 5, 2025 / Vicore Pharma Holding AB (publ) (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback